Industry analysis
Healthcare Service Provider
Read from what its listed companies are showing. Valuations are compared within this industry.
Mixed
36 listed companies · ₹ 77,534 Cr. total market value- ▲74% of companies grew sales by more than 8% from a year earlier; the typical company's profit rose 25%. 20% made a loss.
- ●2 credit rating upgrades and no downgrades in the last 90 days.
- –8 good and no bad company announcements (read since 6 Oct 2026; not counted until there is a month of them).
- ▼The typical share is down 7.7% in 3 months; 35% of shares trade above their 200-day average (their usual level).
- –Typical P/E 21, close to these companies' usual level.
- –Raised ₹ 92 Cr. by issuing shares (1 issue) in 90 days; 2 more fund raises on the way.
▲ / ▼ / ● are the signals the verdict counts: results, credit ratings, announcements and share prices. Lines marked – are shown but not counted.
In charts
Share prices over the last year
The typical Healthcare Service Provider share against the typical share on the market, both starting at 100. Now 82 vs 83.
Is growth speeding up or slowing down?
The typical company's sales and profit growth against the same quarter a year earlier.
Price against growth
Each dot is a company: further left is cheaper (lower P/E), higher up grew profit faster. Red dots passed the cheaper-than-peers screen. Companies beyond the chart's edges sit on the edge.
Cheaper than peers
Not a buy list. These shares trade at a P/E at least 30% below their industry's typical level and below their own usual level, and they also pass basic checks: profitable, sales and profit growing, low debt, no red flags, market value of ₹250 Cr or more. Cheap shares are often cheap for a reason; this is where to start reading, not where to stop.
| Details | ||||
|---|---|---|---|---|
| One Global Service Provider ONEGLOBAL | 12.4 vs 2141% cheaper | +17% / +40% | ₹ 720.96 Cr. |
Cheaper than peers across the whole market
Leaders and laggards
Good news
- Nephrocare Health ServicesCredit rating raised
- Chandan HealthcareStrong results
- Metropolis HealthcareRating outlook raised
Warning signs
No red flags in 90 days.
Best shares, 3 months
- Boston Commerce Ltd+110.3%
- Choksi Laboratories+92.7%
- Suraksha Diagnostic+25.4%
- Modern Diagnostic & Research Centre Ltd+13.5%
- Aspira Pathlab & Diagnostics+12.7%
Worst shares, 3 months
Companies
Click a column to sort.
Figures are medians and shares of companies, so one giant company cannot outweigh the rest. Results compare each company's latest quarter with the same quarter a year earlier; ratings and announcements cover the last 90 days (announcements are read by AI and can be wrong). This page adds up published data; it is not a recommendation to buy or sell anything.